DE602007006040D1 - Hemmstoffe des progesteron-rezeptors - Google Patents

Hemmstoffe des progesteron-rezeptors

Info

Publication number
DE602007006040D1
DE602007006040D1 DE602007006040T DE602007006040T DE602007006040D1 DE 602007006040 D1 DE602007006040 D1 DE 602007006040D1 DE 602007006040 T DE602007006040 T DE 602007006040T DE 602007006040 T DE602007006040 T DE 602007006040T DE 602007006040 D1 DE602007006040 D1 DE 602007006040D1
Authority
DE
Germany
Prior art keywords
ingredients
progesterone receptor
progesterone
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007006040T
Other languages
English (en)
Inventor
Ulrike Fuhrmann
Anja Schmidt
Arwed Cleve
Orlin Petrov
Gunnar Garke
Stefan Pruehs
Margarete Brudny-Kloeppel
Antje Rottmann
Rainer Hasselmann
Marcus Schultze-Mosgau
Carsten Moeller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of DE602007006040D1 publication Critical patent/DE602007006040D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
DE602007006040T 2006-11-15 2007-11-14 Hemmstoffe des progesteron-rezeptors Active DE602007006040D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006054535A DE102006054535A1 (de) 2006-11-15 2006-11-15 Progesteronrezeptorantagonisten
PCT/EP2007/009997 WO2008058767A1 (en) 2006-11-15 2007-11-14 Progesterone receptor antagonists

Publications (1)

Publication Number Publication Date
DE602007006040D1 true DE602007006040D1 (de) 2010-06-02

Family

ID=39243738

Family Applications (2)

Application Number Title Priority Date Filing Date
DE102006054535A Withdrawn DE102006054535A1 (de) 2006-11-15 2006-11-15 Progesteronrezeptorantagonisten
DE602007006040T Active DE602007006040D1 (de) 2006-11-15 2007-11-14 Hemmstoffe des progesteron-rezeptors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE102006054535A Withdrawn DE102006054535A1 (de) 2006-11-15 2006-11-15 Progesteronrezeptorantagonisten

Country Status (41)

Country Link
US (1) US8053426B2 (de)
EP (1) EP2081951B1 (de)
JP (1) JP5260537B2 (de)
KR (1) KR101494914B1 (de)
CN (1) CN101541823B (de)
AR (1) AR063813A1 (de)
AT (1) ATE465169T1 (de)
AU (1) AU2007321848B2 (de)
BR (1) BRPI0718409A2 (de)
CA (1) CA2669767C (de)
CL (1) CL2007003266A1 (de)
CO (1) CO6180443A2 (de)
CY (1) CY1110671T1 (de)
DE (2) DE102006054535A1 (de)
DK (1) DK2081951T3 (de)
EA (1) EA017038B1 (de)
EC (1) ECSP099337A (de)
ES (1) ES2343915T3 (de)
GT (1) GT200900128A (de)
HK (1) HK1136302A1 (de)
HN (1) HN2009000997A (de)
HR (1) HRP20100366T1 (de)
IL (1) IL198650A (de)
JO (1) JO2672B1 (de)
MA (1) MA30990B1 (de)
MX (1) MX2009005212A (de)
NO (1) NO20092284L (de)
NZ (1) NZ576927A (de)
PA (1) PA8755801A1 (de)
PE (1) PE20081409A1 (de)
PL (1) PL2081951T3 (de)
PT (1) PT2081951E (de)
RS (1) RS51369B (de)
SI (1) SI2081951T1 (de)
SV (1) SV2009003260A (de)
TN (1) TN2009000185A1 (de)
TW (1) TW200831109A (de)
UA (1) UA98312C2 (de)
UY (1) UY30718A1 (de)
WO (1) WO2008058767A1 (de)
ZA (1) ZA200904150B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) * 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
EP2868320A1 (de) 2013-11-03 2015-05-06 Flamina Holding AG Zusammensetzung oder Gruppe von Zusammensetzungen zur Behandlung von menschlichen Zellen
RU2017112748A (ru) 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. Композиции онапристона пролонгированного действия и способы
WO2017053793A1 (en) 2015-09-25 2017-03-30 Arno Therapeutics, Inc. Methods of making onapristone intermediates
US10548905B2 (en) 2015-12-15 2020-02-04 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
EP3214092A1 (de) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs vom selektiven progesteronrezeptormodulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-on
JP2019513706A (ja) * 2016-03-21 2019-05-30 コンテキスト・バイオファーマ・インコーポレイテッド オナプリストン代謝物質組成物及び方法
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
CN86102502B (zh) * 1986-08-29 1988-06-22 上海市计划生育科学研究所 11，17位双取代δ4，9-雌甾二烯化合物的合成方法
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19535572B4 (de) * 1994-09-14 2007-02-01 Schering Ag Verfahren zur Herstellung von 17 α-Fluor-steroid-ketonen
WO1996015794A1 (en) * 1994-11-22 1996-05-30 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
WO1998005679A2 (en) 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en) * 1997-06-18 2001-08-23 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
DE19929715A1 (de) * 1999-06-24 2000-12-28 Schering Ag 11ß-langkettig-substituierte Estratriene, Verfahren zur Herstellung , pharmazeutische Präparate, die diese 11ß-langkettig-substituierten Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE10049736A1 (de) * 2000-09-29 2002-04-18 Jenapharm Gmbh 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
CZ299945B6 (cs) * 2000-10-18 2008-12-29 Schering Aktiengesellschaft Lécivo obsahující 17alfa-fluoralkylsteroid pro lécení karcinomu prsu rezistentního vuci steroidum
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
DE10221034A1 (de) * 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
DE50301507D1 (de) 2002-05-03 2005-12-01 Schering Ag 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten

Also Published As

Publication number Publication date
AU2007321848B2 (en) 2013-09-19
KR20090079995A (ko) 2009-07-22
US20080200440A1 (en) 2008-08-21
JO2672B1 (en) 2012-06-17
CN101541823A (zh) 2009-09-23
DK2081951T3 (da) 2010-08-09
ES2343915T3 (es) 2010-08-12
JP2010509386A (ja) 2010-03-25
WO2008058767A1 (en) 2008-05-22
ECSP099337A (es) 2009-06-30
SV2009003260A (es) 2009-12-14
ATE465169T1 (de) 2010-05-15
CL2007003266A1 (es) 2008-07-04
PA8755801A1 (es) 2009-08-26
EA200900635A1 (ru) 2009-12-30
HN2009000997A (es) 2011-10-19
GT200900128A (es) 2012-02-01
TN2009000185A1 (en) 2010-10-18
EP2081951A1 (de) 2009-07-29
NO20092284L (no) 2009-08-13
HRP20100366T1 (hr) 2010-07-31
CA2669767C (en) 2014-04-01
MA30990B1 (fr) 2009-12-01
DE102006054535A1 (de) 2008-05-21
CN101541823B (zh) 2012-10-03
CO6180443A2 (es) 2010-07-19
PL2081951T3 (pl) 2010-09-30
NZ576927A (en) 2012-01-12
UA98312C2 (en) 2012-05-10
CA2669767A1 (en) 2008-05-22
BRPI0718409A2 (pt) 2013-12-17
PE20081409A1 (es) 2008-12-05
US8053426B2 (en) 2011-11-08
TW200831109A (en) 2008-08-01
JP5260537B2 (ja) 2013-08-14
CY1110671T1 (el) 2015-06-10
AU2007321848A1 (en) 2008-05-22
IL198650A0 (en) 2010-02-17
IL198650A (en) 2012-05-31
MX2009005212A (es) 2009-05-27
EA017038B1 (ru) 2012-09-28
UY30718A1 (es) 2008-07-03
KR101494914B1 (ko) 2015-02-23
HK1136302A1 (en) 2010-06-25
AR063813A1 (es) 2009-02-18
ZA200904150B (en) 2010-11-24
SI2081951T1 (sl) 2010-08-31
RS51369B (en) 2011-02-28
PT2081951E (pt) 2010-07-01
EP2081951B1 (de) 2010-04-21

Similar Documents

Publication Publication Date Title
DE602007006040D1 (de) Hemmstoffe des progesteron-rezeptors
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
ES2411907T8 (es) Uso terapéutico de anticuerpos antirreceptor TWEAK
BRPI0817879A2 (pt) Composições e métodos de uso de anticorpos contra esclerostina
DK1986650T3 (da) Manipulationssikre doserignsformer
DK2077729T3 (da) Orale probiotiske doseringsformer
DK2069403T3 (da) Human-antistoffer med høj affinitet for human IL-4 receptor
PL1981915T3 (pl) Kompozycje składników aktywnych
BRPI0906980A2 (pt) Composição de derivados e maleatados
BRPI0911563A2 (pt) uso de antagonista da progesterona
FR2918570B1 (fr) DIGLYCATION DES AGEs.
CR10562A (es) Nuevos derivados de piridazina
PL1816116T3 (pl) Kompozycje chemiczne i sposoby ich wytwarzania
BRPI0716458A2 (pt) Composição de vulcanizado
HK1137738A1 (en) Hydrogenation of caryophyllene
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
FI20065834A0 (fi) Iskulaite
BRPI0718141A2 (pt) Composições de frangrâncias
BRPI0719228A2 (pt) Composição estabilizada de prostaglandina e
DK2067019T3 (da) Fremgangsmåde med multikapillarer til prøvepræparering
DK1971633T3 (da) Indpakkkede detergentsammensætninger og fremgangsmåde til deres fremstilling
ZA200900242B (en) Use of glucocorticoid receptor antagonists for treatment of infectious conditions
ATE469900T1 (de) Spiropiperidinderivate als antagonisten des via- rezeptors
ATE478078T1 (de) Pyridooxazepin-progesteronrezeptor-modulatoren
ITMI20061912A1 (it) Composizioni farmaceutiche topiche vaginali

Legal Events

Date Code Title Description
8364 No opposition during term of opposition